Literature DB >> 8242270

A longitudinal study of exercise metabolism during recovery from viral illness.

P Jakeman1.   

Abstract

An élite athlete engaged in a longitudinal programme of physiological assessment suffered a loss of performance that was later ascribed to an asymptomatic viral illness. In this 15-month, single subject, repeated measures study it was possible to demonstrate a severe decrease of exercise performance following viral illness. The oxygen uptake equivalent to the onset of blood lactate accumulation of 4 mmol l-1 (OBLA) decreased by 17% following viral illness, then recovered slowly, but had not returned to pre-viral levels 50 weeks later. Steady state exercise metabolism was also affected. During prolonged exercise at 70% of VO2max the proportion of energy derived from carbohydrate metabolism increased and an inability to maintain euglycaemia was observed. In both the graded and prolonged exercise tests, a pronounced tachycardia was evident after viral illness, possibly as a result of a febrile response to the infection, or, a direct effect of the virus upon myocardial performance. These data provide some preliminary and unique findings of the effects of viral illness upon the physiological and metabolic responses to exercise in an élite athlete. The data also demonstrate the sensitivity of currently used laboratory measures of exercise performance to monitor the changes in physiological function during recovery from viral illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242270      PMCID: PMC1332178          DOI: 10.1136/bjsm.27.3.157

Source DB:  PubMed          Journal:  Br J Sports Med        ISSN: 0306-3674            Impact factor:   13.800


  19 in total

1.  Chronic fatigue syndrome: a working case definition.

Authors:  G P Holmes; J E Kaplan; N M Gantz; A L Komaroff; L B Schonberger; S E Straus; J F Jones; R E Dubois; C Cunningham-Rundles; S Pahwa
Journal:  Ann Intern Med       Date:  1988-03       Impact factor: 25.391

2.  Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.

Authors:  A M Bakheit; P O Behan; T G Dinan; C E Gray; V O'Keane
Journal:  BMJ       Date:  1992-04-18

3.  Determinants of endurance in well-trained cyclists.

Authors:  E F Coyle; A R Coggan; M K Hopper; T J Walters
Journal:  J Appl Physiol (1985)       Date:  1988-06

4.  Impaired carbohydrate metabolism during a mild viral illness.

Authors:  E J Rayfield; R T Curnow; D T George; W R Beisel
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

5.  A simple, rapid method for the determination of glucose, lactate, pyruvate, alanine, 3-hydroxybutyrate and acetoacetate on a single 20-mul blood sample.

Authors:  R J Maughan
Journal:  Clin Chim Acta       Date:  1982-07-01       Impact factor: 3.786

6.  Effects of viral and mycoplasma infections on ultrastructure and enzyme activities in human skeletal muscle.

Authors:  E Aström; G Friman; L Pilström
Journal:  Acta Pathol Microbiol Scand A       Date:  1976-03

7.  Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.

Authors:  E Byrne; I Trounce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

8.  Effects of increased plasma fatty acids on glycogen utilization and endurance.

Authors:  R C Hickson; M J Rennie; R K Conlee; W W Winder; J O Holloszy
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-11

9.  Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. A 31P nuclear magnetic resonance study.

Authors:  D L Arnold; P J Bore; G K Radda; P Styles; D J Taylor
Journal:  Lancet       Date:  1984-06-23       Impact factor: 79.321

Review 10.  Viral illnesses and sports performance.

Authors:  J A Roberts
Journal:  Sports Med       Date:  1986 Jul-Aug       Impact factor: 11.136

View more
  1 in total

1.  Febrile illness in the athlete.

Authors:  Natalie A Dick; Jason J Diehl
Journal:  Sports Health       Date:  2014-05       Impact factor: 3.843

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.